An expert discusses how recent research surprisingly shows vitiligo lesions do not have increased skin cancer risk, fundamentally changing patient counseling from emphasizing cancer prevention to focusing on sunburn protection and addressing the profound psychosocial effects on career choices, relationships and life trajectory across all socioeconomic levels.
An expert discusses how the lack of transparency in medication pricing creates a "black box" between actual drug costs and patient expenses, negatively affecting both patient care and the health care system's ability to provide effective vitiligo treatments.
An expert discusses how insurance coverage barriers for Janus kinase (JAK) inhibitors in vitiligo treatment can be overcome by demonstrating medical necessity, especially for visible areas such as the face and hands, while emphasizing the cultural and social stigma that makes treatment essential rather than cosmetic.
An expert discusses how systemic treatments for vitiligo often have better patient adherence than topical treatments, though they require blood work monitoring and careful consideration of cardiovascular and other health risks.
